Skip to main content

Table 1 The demographic and clinical characteristics of RA patients at baseline in the full analysis set

From: Traditional Chinese medicine Biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial

CharacteristicsMTX + Biqi (n = 35)MTX + LEF (n = 35)P value
Age (SD), years42.74 (10.35)44.40 (11.36)0.526
Female, n (%)32 (91.43)31 (88.57)0.690
Disease duration (SD), months26.12 (31.46)35.19 (33.45)0.136
TJC (SD), n8.97 (6.31)8.29 (6.42)0.544
SJC (SD), n6.03 (5.34)4.23 (3.03)0.246
Patient’s assessment of pain (SD), mm58.57 (24.54)56.29 (21.43)0.678
PhGADA(SD), mm52.09 (25.53)52.00 (20.37)1.000
PaGADA(SD), mm55.71 (25.61)53.00 (20.37)0.673
Morning stiffness (SD), min69.00 (53.99)56.03 (49.06)0.365
HAQ, mean ± SD1.02 (0.81)0.73 (0.73)0.116
hs-CRP (SD), mg/L12.45 (18.76)15.88 (17.27)0.259
ESR (SD), mm/h44.49 (27.20)54.86 (27.13)0.115
RF# (SD), U/mL153.55 (162.72)174.33 (183.97)0.787
Anti-CCP#, positive rate28 (84.85)29 (82.86)1.000
DAS28 (SD)4.66 (1.39)4.55 (1.22)0.742
NSAIDs, n (%)29 (82.9%)28 (80.0%)0.759
Glucocorticoid oral, n (%)6 (20.0%)14 (37.1%)0.112
Folic acid tablet, n (%)23 (65.7%)27 (77.1%)0.290
Antacids, n (%)27 (77.1%)26 (74.3%)0.780
  1. Data are presented as the mean (SD) or n (%)
  2. TJC tender joint count, SJC swollen joint count, PaGADA patient’s global assessment of disease activity, PhGADA physician’s global assessment of disease activity, HAQ Health Assessment Questionnaire, ESR erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptide antibody, DAS28 28-joint disease activity score, cDAI clinical disease activity index
  3. RF# was measured by immunonephelometry with a cut-off value of 20 U/mL. Anti-CCP# was measured using a commercially available second-generation ELISA kit (Abbott, USA) with a cut-off value of 25 U/mL
  4. Measured on a 100-mm visual analog scale. NSAID: nonsteroidal anti-inflammatory drug